Want to learn more about how engaging T-cells via bispecific antibodies can change the course of cancer treatment? LAVA’s EVP, Head of R&D Paul Parren, PhD is chairing the ‘Bispecific T cell Engagers’ session at the Antibody Engineering and Therapeutics conference on Monday, December 14. LAVA’s CSO, and Hans van der Vliet, MD, PhD, will be on the panel. More information.